NEW YORK, October 28, 2016 /PRNewswire/ --
On Thursday, October 27, 2016, the NASDAQ Composite ended the trading session at 5,215.97, down 0.65%; the Dow Jones Industrial Average edged 0.16% lower, to finish at 18,169.68; and the S&P 500 closed at 2,133.04, down 0.30%. Stock-callers.com looks at the performance of these three companies from the specialized health services: DaVita Inc. (NYSE: DVA), Acadia Healthcare Company Inc. (NASDAQ: ACHC), and AmSurg Corporation (NASDAQ: AMSG). Download the free research reports on these stocks today:
On Thursday, shares in Denver, Colorado headquartered DaVita Inc. ended the session 1.64% lower at $55.93 with a total volume of 1.75 million shares traded. DaVita Inc.'s shares are trading 12.53% below its 50-day moving average and 20.69% below its 200-day moving average. Moreover, shares of the Company, which provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease, are trading at a PE ratio of 33.04 and have a Relative Strength Index (RSI) of 20.39. See our free and comprehensive research report on DVA at:
Franklin, Tennessee headquartered Acadia Healthcare Co. Inc.'s stock finished Thursday's session 1.91% lower at $36.96 with a total volume of 1.31 million shares traded. Shares of the Company, which develops and operates inpatient psychiatric facilities, residential treatment centers, group homes, substance abuse facilities, and outpatient behavioral healthcare facilities to serve the behavioral health and recovery needs of communities in the US, the UK, and Puerto Rico, are trading at a PE ratio of 20.20. The Company's shares are trading below its 50-day and 200-day moving averages by 23.44% and 32.25%, respectively. Acadia Healthcare's stock has an RSI of 24.44.
On October 19th, 2016, research firm UBS reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $79 a share to $55 a share. ACHC free research report PDF is just a click away at:
Nashville, Tennessee headquartered AmSurg Corp.'s stock fell 5.14%, to close the day at $58.48. The stock recorded a trading volume of 2.54 million shares, which was above its three months average volume of 1.12 million shares. Shares of AmSurg, which through its subsidiaries, provides physician-centric surgical center and physician services in the US, are trading 10.66% and 18.64% below its 50-day and 200-day moving averages, respectively. Additionally, the stock traded at a PE ratio of 18.57 and has an RSI of 31.89. Sign up for your complimentary report on AMSG at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA